The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

NeoGenomics, Inc. (NASDAQ:NEO) is one of the top 10 medical AI companies to buy according to analysts. On July 30, the company announced the launch of NEO PanTracer LBx, a blood-based comprehensive ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

Liquid biopsy has increasingly been adopted and explored for clinical care, but careful analytic and clinical validation, as well as additional preclinical studies addressing the biology of liquid ...

Liquid biopsy detected targetable mutations in one-third of patients (n = 33) who opted for that test alone.

The researchers also followed a patient for 2.5 years and found that they could detect EML4-ALK in the liquid biopsy a good two months before it was possible to use radiography to confirm the disease.

The liquid biopsy showed her cancer had developed what’s called resistance to Tarceva, but suggested it might be knocked back by a newer drug called Tagrisso, or osimertinib. It’s another pill.

On-Q-ity, a liquid biopsy startup based in Waltham, Mass., folded in 2013. One of its investors said the technology would likely not be market-ready for another five to 10 years.